RxSight's Single-Product Story: Tomorrow We Learn If Adjustability Justifies the Wait

RxSight (NASDAQ: RXST) reports first-quarter 2026 earnings tomorrow, May 6, after market close, with analysts expecting a loss of -$0.30 per share—significantly wider than the prior quarter's -$0.22 loss. The central question is whether the medtech company can stabilize its financial trajectory after recent estimate deterioration, or if mounting losses will deepen investor concerns about the path to profitability for its Light Adjustable Lens system.

Part 1: Earnings Preview

RxSight is a medical technology company specializing in ophthalmic devices, best known for its FDA-approved Light Adjustable Lens (LAL) system—the only intraocular lens that enables post-surgical vision customization for cataract patients. The company generates revenue primarily through lens sales and the expansion of installed Light Delivery Devices (LDDs), positioning itself as a differentiated player in the refractive cataract surgery market.

For Q1 2026, analysts expect RxSight to report a loss of -$0.30 per share on estimated revenue of approximately $29.75 million. The most recently reported quarter (Q4 2025) delivered a loss of -$0.22 per share, representing a sequential improvement from Q3's -$0.24 loss. Year-over-year, the Q1 2026 estimate of -$0.30 compares to a loss of -$0.20 per share in Q1 2025, indicating a 50% deterioration in profitability expectations.

Three key themes define this earnings story:

Revenue Execution and Guidance Reset: Following the company's 2026 revenue guidance of $120 million to $135 million—down from prior expectations—investors are watching whether Q1 results validate management's recalibrated outlook or signal further downside risk. Recent analyst commentary describes current Street forecasts as "comfortable," but execution consistency remains critical after multiple quarters of revenue volatility.

Path to Profitability and Margin Trajectory: With losses expected to widen both sequentially and year-over-year, the focus is on whether RxSight can demonstrate progress on gross margin expansion through manufacturing scale and operating expense discipline. Analysts have noted that the balance between continued R&D investment and the march toward profitability is a key metric for assessing long-term viability.

Market Adoption and Surgeon Training: The expansion rate of installed LDDs, procedure volumes, and surgeon training programs are critical leading indicators of recurring revenue growth. Management commentary on geographic expansion, reimbursement developments, and competitive positioning will provide insight into whether the LAL system is gaining sustainable traction with refractive cataract surgeons.

Analyst sentiment heading into the release is cautious. Recent research reflects "a mix of cautious optimism and lingering questions around execution, valuation and the setup after recent share price moves," with most firms holding neutral ratings. Price targets cluster in the $9 to $10 range, with the consensus at $9.93—implying modest upside from current levels. One analyst noted that "updated 2026 guidance, Q4 results and leadership changes" have been incorporated into models, while another highlighted that "execution quality" and the new CFO appointment are key factors supporting the story. However, multiple analysts cite "consecutive quarterly misses and lowered guidance as primary concerns," and some have described the current setup as requiring sustained outperformance to justify higher valuations.

Part 2: Historical Earnings Performance

RxSight's recent earnings history reveals a pattern of significant estimate beats in the second half of 2025, following earlier misses. In Q1 2025, the company missed expectations by -17.65%, reporting a loss of -$0.20 per share against an estimate of -$0.17. Q2 2025 saw another modest miss of -3.57%, with a loss of -$0.29 versus an estimate of -$0.28.

The trend reversed sharply in the latter half of the year. Q3 2025 delivered a +29.41% beat, reporting -$0.24 against an estimate of -$0.34, followed by an even stronger +46.34% beat in Q4 2025, with a loss of -$0.22 versus an estimate of -$0.41. This two-quarter streak of substantial outperformance suggests improved operational execution and potentially conservative analyst modeling in recent quarters.

However, the current Q1 2026 estimate of -$0.30 represents a 50% deterioration from the -$0.20 loss reported in Q1 2025, indicating that analysts expect profitability challenges to persist despite the recent positive surprises. The question is whether RxSight can extend its beat streak or if the widening loss estimate reflects genuine headwinds that will materialize in the results.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

RxSight typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows moderate volatility around RxSight earnings, with an average absolute Day 0 move of 3.49% and a Day +1 move of 5.68%. The Day +1 reaction tends to be larger and more decisive, consistent with after-hours reporting where the full market response unfolds the following session.

The most recent earnings (February 2025) saw relatively muted movement, with Day 0 down just 1.45% and Day +1 down 10.10%. However, prior quarters exhibited more dramatic swings—November 2025 saw a 7.33% Day 0 decline followed by a 3.24% Day +1 recovery, while May 2025 posted a 6.81% Day 0 gain that reversed to an 11.21% Day +1 decline. The average Day +1 range of 12.99% indicates that investors should prepare for significant intraday volatility regardless of the initial direction. Given the recent pattern of estimate beats but widening year-over-year losses, the market's reaction will likely hinge on whether management can provide confidence in the revised 2026 guidance and demonstrate tangible progress toward profitability.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.20% expected move for the May 15 expiration, which is above the historical average Day +1 move of 5.68% but below the average Day +1 range of 12.99%. This suggests options traders are anticipating elevated volatility, though not at the extreme levels seen in some prior quarters. The implied move aligns more closely with the upper end of recent earnings reactions, indicating the market is bracing for a potentially significant response to the results and guidance commentary.

Part 3: What Analysts Are Saying

Analyst sentiment on RxSight is cautious and predominantly neutral, with a consensus rating of 2.80 (between Sell and Hold) and an average price target of $9.93. The current breakdown shows 1 Moderate Buy, 7 Holds, 1 Moderate Sell, and 1 Strong Sell—a distribution that reflects skepticism about near-term upside despite the company's differentiated technology.

The consensus price target of $9.93 implies 36.8% upside from the current price of $7.26, suggesting analysts see value at current levels but lack conviction for aggressive bullishness. Price targets range from a low of $8.00 to a high of $13.00, with most clustering in the $9 to $10 range. Sentiment has remained unchanged over the past month, with no shifts in the rating distribution—indicating analysts are in a wait-and-see mode ahead of the Q1 report.

Recent analyst commentary reflects this cautious stance. Multiple firms have described the current setup as requiring "sustained outperformance" to justify higher valuations, while others note that "execution quality" and the new CFO appointment are supportive factors. However, concerns persist around "consecutive quarterly misses and lowered guidance," with some analysts highlighting that "slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution" remain key risks. The tight clustering of price targets and neutral ratings suggests the Street is waiting for clearer evidence that RxSight can deliver on its recalibrated 2026 guidance before upgrading their outlook.

Part 4: Technical Picture

RxSight enters earnings with a deteriorating technical setup that has weakened significantly over recent months. The Barchart Technical Opinion currently stands at 48% Sell, improving slightly from 64% Sell a week ago and 72% Sell a month ago. While the near-term signal has shown modest improvement, the overall technical picture remains bearish.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stabilized after recent weakness, though without clear directional conviction
• Medium-term (50% Sell): Moderate sell signal indicates intermediate-term pressure remains, reflecting the stock's inability to establish a sustained uptrend
• Long-term (100% Sell): Strong sell signal confirms the longer-term trend is decisively negative, with the stock well below key moving averages

Trend Characteristics: The trend is characterized as Weak and Weakening, indicating that while the stock has shown some recent stabilization, the underlying momentum remains fragile and vulnerable to further downside if earnings disappoint.

The stock is trading at $7.26, positioned above its 5-day ($7.18), 10-day ($7.22), 20-day ($7.21), and 50-day ($7.20) moving averages—suggesting very short-term stabilization. However, it remains below both the 100-day ($8.56) and 200-day ($8.78) moving averages, confirming the longer-term downtrend remains intact. The stock has declined approximately 17% from its 100-day average and 17.3% from its 200-day average, underscoring the magnitude of the technical damage. The clustering of short-term moving averages near current levels creates a narrow support zone, but the lack of upside momentum and distance from longer-term averages leaves the stock vulnerable to a sharp move lower if earnings or guidance disappoint. Conversely, a strong beat and improved outlook could trigger a technical reversal, though the stock would need to reclaim the $8.50+ area to signal a meaningful trend change. Overall, the technical setup is cautionary heading into earnings, with limited cushion for disappointment.